ACAD compared with SMMT: revenue, margins and what each company keeps, and the suppliers and customers both name

ACADAcadia Pharmaceuticals Inc

Mkt capRevenueRevenue

SMMTSummit Therapeutics Inc.

Mkt capRevenueRevenue

Compare

ACADAcadia Pharmaceuticals Inc

SMMTSummit Therapeutics Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ACAD

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±11.9%▲+6.08%×0.51

May 7 '26±13.4%▲+5.03%×0.37

Q1 FY26±9.4%▼−1.32%×0.14

Jan 13 '26±6.6%▼−0.49%×0.08

SMMT1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−8.81%—

= impliedACAD realized, solidSMMT realized, hatchedOne scale, both sides: full bar = 14%× = |realized| ÷ impliedSource: market data

ACADAcadia Pharmaceuticals Inc

20.46· pre 20.42· delayed

Mkt cap$3.5BRevenue$308MQ2 FY26Revenue$1.1BFY25

SMMTSummit Therapeutics Inc.

14.81· pre 14.81· delayed

Pre-marketNov 2 '26delayed

Mkt cap$11.8BRevenue—Revenue—

Compare

Pre-marketNov 2 '26delayed

ACADAcadia Pharmaceuticals Inc

SMMTSummit Therapeutics Inc.

20.46pre 20.42delayed

Price

14.81pre 14.81delayed

$3.5B

Mkt cap

$11.8B

Q2 FY26$308M

Revenue

—

FY25$1.1B

Revenue

—

ACAD20.46vsSMMT14.81Pre-marketNov 2 '26delayed